Literature DB >> 17659780

An in vitro model of T cell receptor revision in mature human CD8+ T cells.

Erica Lantelme1, Luca Orlando, Paola Porcedda, Valentina Turinetto, Mario De Marchi, Antonio Amoroso, Stefania Mantovani, Claudia Giachino.   

Abstract

V(D)J recombination is a mechanism peculiar to the somatic rearrangement of antigen receptor genes. It requires both expression of the RAG-1 and RAG-2 recombinases and accessibility of the substrate to its recombinase and post-cleavage/DNA repair stage. TCR revision is a genetic correction mechanism that changes T cell specificity by re-activating V(D)J recombination in peripheral T cells. This process is now well described in both normal or pathological murine and human settings. Many of its features, such as the question of whether it occurs in truly mature T cells, remain to be elucidated. Its occurrence in human CD8+ T cells is also an open question. We have therefore established an in vitro model of TCR revision in mature human CD8+ T cells to determine whether down-regulation of the TCR/CD3 complex from the cell surface in the presence of IL7 as a factor favouring chromatin remodelling initiates a TCR revision pathway. Only mature CD8+ T cells carrying already-formed antigen receptors were used. CD8+ T cells treated with anti-CD3 and IL7 showed rearrangement intermediates and expressed new Vbeta-chains on their surface. Investigation of the molecular pathway thus induced disclosed up-regulation of the RAG-2 transcript, but absence of the 'canonical' RAG-1 mRNA. A surprising finding was the demonstration of alternative splice forms of this mRNA, already expressed in untreated CD8+ T cells, encoding for the full-length RAG-1 protein, which was increased three-fold in the treated cells. All the V(D)J requirements were thus fulfilled when mature human CD8+ T cells were stimulated with anti-CD3 and IL7. Induction of TCR revision in vitro in mature T cells is an easily controllable system that could be employed in further studies to elucidate the molecular pathways involved in secondary V(D)J rearrangements in peripheral cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17659780     DOI: 10.1016/j.molimm.2007.06.153

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  8 in total

1.  TCR revision generates functional CD4+ T cells.

Authors:  J Scott Hale; Maramawit Wubeshet; Pamela J Fink
Journal:  J Immunol       Date:  2010-10-22       Impact factor: 5.422

Review 2.  Of the multiple mechanisms leading to type 1 diabetes, T cell receptor revision may play a prominent role (is type 1 diabetes more than a single disease?).

Authors:  D H Wagner
Journal:  Clin Exp Immunol       Date:  2016-07-25       Impact factor: 4.330

3.  Modulation of TCRβ surface expression during TCR revision.

Authors:  Kalynn B Simmons; Maramawit Wubeshet; Kristina T Ames; Catherine J McMahan; J Scott Hale; Pamela J Fink
Journal:  Cell Immunol       Date:  2011-11-15       Impact factor: 4.868

Review 4.  T-cell receptor revision: friend or foe?

Authors:  J Scott Hale; Pamela J Fink
Journal:  Immunology       Date:  2010-02-26       Impact factor: 7.397

Review 5.  The dynamic lives of T cells: new approaches and themes.

Authors:  Yvonne J Yamanaka; Todd M Gierahn; J Christopher Love
Journal:  Trends Immunol       Date:  2012-11-28       Impact factor: 16.687

6.  Generation of functional, antigen-specific CD8+ human T cells from cord blood stem cells using exogenous Notch and tetramer-TCR signaling.

Authors:  Irina Fernandez; Tracy P Ooi; Krishnendu Roy
Journal:  Stem Cells       Date:  2014-01       Impact factor: 6.277

7.  Human Peripheral CD4(+) Vδ1(+) γδT Cells Can Develop into αβT Cells.

Authors:  Hendrik Ziegler; Christian Welker; Marco Sterk; Jan Haarer; Hans-Georg Rammensee; Rupert Handgretinger; Karin Schilbach
Journal:  Front Immunol       Date:  2014-12-17       Impact factor: 7.561

8.  Somatic hypermutation of T cell receptor α chain contributes to selection in nurse shark thymus.

Authors:  Jeannine A Ott; Caitlin D Castro; Thaddeus C Deiss; Yuko Ohta; Martin F Flajnik; Michael F Criscitiello
Journal:  Elife       Date:  2018-04-17       Impact factor: 8.140

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.